New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

Targeted therapy has opened a new era in treatment of patients with non-small-cell lung cancer associated with mutations of the epidermal growth factor receptor (EGFR) gene. However, most patients after starting targeted therapy develop progression within 10-12 months. The basic mechanisms of acquir...

Full description

Bibliographic Details
Main Authors: K K Laktionov, E V Reutova, L A Nelyubina, M Yu Pitkevich, M A Okruzhnova, M S Ardzinba, D I Yudin, I A Demidova, A R Zaretsky
Format: Article
Language:Russian
Published: IP Habib O.N. 2018-06-01
Series:Современная онкология
Subjects:
non-small-cell lung cancer
egfr tyrosine kinase inhibitors
osimertinib
acquired resistance
the t790m mutation
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/29551/pdf

Internet

https://modernonco.orscience.ru/1815-1434/article/viewFile/29551/pdf

Similar Items